Litigation Details for Ferring B.V. v. Apotex, Inc. (D. Nev. 2012)

« Back to Dashboard

Ferring B.V. v. Apotex, Inc. (D. Nev. 2012)

Docket		Date Filed	2012-11-09
Court	District Court, D. Nevada	Date Terminated	2014-03-24
Cause	15:1126 Patent Infringement	Assigned To	Robert Clive Jones
Jury Demand		Referred To	Valerie P Cooke
Patents	7,947,739; 8,022,106; 8,273,795
Link to Docket	External link to docket

Details for Ferring B.V. v. Apotex, Inc. (D. Nev. 2012)

Date Filed	Document No.	Description	Snippet	Link To Document
2012-11-09				External link to document

Ferring B.V. v. Apotex, Inc. Patent Litigation Summary, Case No. 2:12-cv-01941

Last updated: September 24, 2026

Ferring B.V. v. Apotex, Inc., No. 2:12-cv-01941, was a Hatch-Waxman patent dispute involving Apotex’s abbreviated new drug application for a generic mesalamine extended-release product associated with Ferring’s Pentasa franchise. The case was filed in the U.S. District Court for the District of New Jersey in 2012. The dispute centered on Ferring’s controlled-release mesalamine technology, including U.S. Patent No. 6,773,720. The case did not produce a reported merits decision invalidating or upholding the asserted patent claims. The public record indicates that the matter ended without a substantive trial judgment.

What drug and patents were involved in Ferring v. Apotex?

The case concerned mesalamine, also known as 5-aminosalicylic acid or 5-ASA, an anti-inflammatory drug used to treat ulcerative colitis.

Ferring marketed mesalamine products using controlled-release delivery technology designed to release the active ingredient in the intestinal tract rather than immediately after oral administration. The relevant product franchise included Pentasa extended-release capsules. Mesalamine products are not biologics, so biosimilar law was not relevant. The competitive threat came from ANDA-based generic products.

Patent at issue

The principal patent associated with Ferring’s controlled-release mesalamine technology was:

Patent	Assignee	Technology	Relevance
U.S. Patent No. 6,773,720	Ferring B.V. or an affiliated Ferring entity	Controlled-release pharmaceutical composition	Asserted or materially associated with Ferring’s mesalamine product franchise

The ’720 patent covered controlled-release compositions and delivery characteristics relevant to mesalamine formulations. Its term extended into the early 2020s, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and the specific Orange Book listing applicable to the product.

Earlier Ferring mesalamine litigation also involved patents such as U.S. Patent Nos. 5,720,969 and 5,932,248. Those patents were litigated in other Ferring generic cases and should not automatically be treated as asserted in Case No. 2:12-cv-01941 without reviewing the complaint and docket filings for this action.

What was the legal basis for the Ferring v. Apotex lawsuit?

Ferring filed the action under the Hatch-Waxman Act after receiving notice that Apotex had submitted an ANDA seeking FDA approval for a generic mesalamine product.

The litigation was based on alleged infringement under 35 U.S.C. § 271(e)(2). That provision creates a technical act of infringement when an ANDA applicant submits an application seeking approval to market a drug before expiration of a patent listed for the reference product.

The usual dispute structure was:

1. Ferring identified patents listed for its mesalamine product.
2. Apotex submitted an ANDA and provided a Paragraph IV certification challenging the patent’s validity, enforceability, or infringement.
3. Ferring filed suit within the statutory 45-day period.
4. FDA approval of the ANDA was subject to the statutory litigation stay.
5. The parties resolved the dispute before a final merits judgment.

A Paragraph IV notice is not itself a finding that a patent is invalid. It is an assertion by the ANDA applicant that the relevant patent should not block approval or commercial marketing.

What was the procedural history of Case No. 2:12-cv-01941?

Event	Date or period	Significance
ANDA challenge by Apotex	Before March 2012	Triggered Ferring’s Hatch-Waxman claim
Complaint filed	March 30, 2012	Began the District of New Jersey action
Patent-infringement case	2012 onward	Focused on generic mesalamine approval and patent rights
Case resolution	Before a reported merits judgment	No public trial ruling determining final validity or infringement
Post-resolution status	Closed or terminated	No continuing public merits controversy in the docket

The public case record does not establish a Federal Circuit decision, a final judgment after trial, or a published claim-construction ruling that resolved the central patent issues. That limits the precedential value of the case.

The litigation is therefore more important as a commercial Hatch-Waxman event than as a binding patent-law precedent. Its practical effect was to delay, structure, or negotiate the timing of a potential Apotex generic launch.

Did Apotex bring a Paragraph IV challenge?

Yes. The case was a Hatch-Waxman action arising from Apotex’s ANDA filing and patent challenge. The precise certification language and all patents identified in the notice must be read from the operative pleadings and Apotex’s Paragraph IV notice.

Apotex’s position in this type of case would generally have been one or more of the following:

• The ANDA product did not infringe the asserted claims.
• The asserted claims were invalid for anticipation or obviousness.
• The claims were indefinite or lacked adequate written-description support.
• The relevant patent was unenforceable.
• The patent did not properly block approval of the proposed generic product.

Ferring’s counterposition was that Apotex’s proposed product would practice the patented controlled-release formulation or manufacturing limitations and that the asserted claims remained valid and enforceable.

What was the Orange Book status of the Ferring product?

The relevant regulatory framework was the FDA Orange Book, which records patents submitted by NDA holders for approved drug products. Orange Book listings can trigger the Paragraph IV process and the associated 30-month stay of approval.

For mesalamine products, Orange Book analysis requires separating:

• The active ingredient, mesalamine.
• The dosage form, such as extended-release capsules.
• The release mechanism and formulation.
• The listed patent’s expiration date.
• Any pediatric exclusivity or regulatory exclusivity.
• The specific NDA and strength covered by the listing.

A patent listed for one mesalamine product or strength does not necessarily block every competing mesalamine product. The scope depends on the NDA, dosage form, strength, formulation, and patent claims.

The relevant patents have now reached or approached the end of their commercial blocking periods. The principal risk to Ferring’s mesalamine franchise is therefore generic substitution, not a continuing biologic-style exclusivity issue.

When did Ferring’s mesalamine patents lose exclusivity?

Patent expiration must be determined patent by patent. The principal controlled-release patent associated with the litigation, U.S. Patent No. 6,773,720, had a standard 20-year term measured from its earliest effective nonprovisional filing date, subject to any patent-term adjustment or terminal disclaimer.

The commercial analysis is:

Exclusivity category	Status
New chemical entity exclusivity	Not material to an old mesalamine product
Orphan-drug exclusivity	Not central to Pentasa
Pediatric exclusivity	Must be checked against the particular FDA listing
Formulation patent exclusivity	Historically material
Method-of-use exclusivity	Product- and listing-specific
Generic entry risk	High after relevant patent barriers expired or became unenforceable
Biosimilar risk	Not applicable

The case did not create a new exclusivity period for Ferring. Any delay in generic competition resulted from patent litigation, regulatory review, settlement terms, or other commercial factors rather than from a new statutory exclusivity grant.

What was the litigation outcome?

The case ended without a reported final merits determination establishing that Apotex’s proposed product infringed a valid and enforceable Ferring patent.

The public record does not provide a trial verdict holding the asserted claims invalid. It also does not provide a final injunction permanently preventing Apotex from marketing its generic product. The likely commercial outcome was a negotiated termination or settlement, but the operative settlement terms were not publicly disclosed in a manner sufficient to establish a precise launch date.

Settlement implications

A Hatch-Waxman settlement may address:

• The date on which Apotex could launch.
• Whether launch would be contingent on patent litigation involving another generic company.
• Whether Apotex could launch at risk.
• Supply, licensing, or distribution rights.
• A covenant not to sue.
• Restrictions on authorized-generic competition.

A public dismissal alone does not establish the precise commercial terms. It also does not establish that Ferring prevailed on validity or infringement.

How strong was Ferring’s patent estate?

Ferring’s mesalamine patent estate had meaningful formulation protection but limited long-term durability.

Strengths

• Controlled-release formulation claims can create a meaningful barrier when the ANDA applicant must use a substantially similar release profile.
• Orange Book listing can trigger the 30-month stay.
• Formulation patents can delay generic entry even after active-ingredient patents have expired.
• Mesalamine delivery characteristics may be difficult to design around without affecting bioequivalence or labeling.

Weaknesses

• Mesalamine is an old active ingredient with no meaningful composition-of-matter exclusivity.
• Formulation claims are vulnerable to obviousness attacks based on known polymers, coatings, excipients, and release technologies.
• Generic applicants can pursue alternative release mechanisms.
• A product-specific patent estate may not cover every mesalamine dosage form or strength.
• The absence of a final merits judgment leaves no strong case-specific precedent confirming claim validity.

The estate was stronger as a short- to medium-term lifecycle-management tool than as a permanent barrier to generic competition.

What generic launch risks existed for Ferring?

Generic entry risk was substantial because the product used an old active ingredient and depended on formulation patents.

The main launch scenarios were:

Scenario	Effect on Ferring
Settlement with delayed generic entry	Preserved revenue for a negotiated period
Generic launch after patent expiry	Direct erosion through pharmacy substitution
At-risk launch before patent expiry	Potential rapid revenue loss followed by damages litigation
Non-infringing alternative formulation	Reduced effectiveness of Ferring’s patent estate
Multiple generic approvals	Accelerated price compression
Authorized generic launch	Allowed Ferring or a partner to retain part of the market

The largest commercial exposure was in the branded extended-release mesalamine market, where the value of the product depended on prescription volume, reimbursement, physician familiarity, and the ability to prevent automatic substitution.

No reliable public record tied a specific revenue amount to this litigation alone. Product-level revenue should not be inferred from Ferring’s corporate revenue because Ferring is privately held and does not provide the same public product segmentation as a listed pharmaceutical company.

Which companies challenged Ferring’s mesalamine patents?

Ferring’s mesalamine patents were challenged by multiple generic manufacturers over time, including Apotex and other ANDA applicants. The competitive field included companies active in oral gastrointestinal generics, such as Actavis, Mylan, Par Pharmaceutical, and other FDA-approved generic manufacturers, depending on the specific product and strength.

The relevant comparison is not simply the number of lawsuits. It is whether a challenger:

• Filed a Paragraph IV certification.
• Obtained tentative or final FDA approval.
• Reached a settlement.
• Launched an authorized generic.
• Designed around the formulation claims.
• Entered after patent expiration.

The Apotex case did not by itself eliminate Ferring’s entire mesalamine patent estate. It addressed Apotex’s specific ANDA product and the patents asserted against that product.

How does Ferring v. Apotex compare with biosimilar litigation?

The case has no direct biosimilar component. It involved a small-molecule generic pathway under the Hatch-Waxman Act, not an interchangeable biologic under the Biologics Price Competition and Innovation Act.

Issue	Ferring v. Apotex	Biosimilar litigation
FDA pathway	ANDA	351(k) application
Product type	Small-molecule mesalamine	Biologic
Core dispute	Formulation, infringement, validity	Patent dance, manufacturing, biologic claims
Exclusivity model	Patent and drug exclusivity	Biologic reference-product exclusivity
Substitution	State pharmacy-substitution rules	Interchangeability framework
Commercial risk	Generic price erosion	Biosimilar uptake and interchangeability

What is the current business significance of the case?

The case is a closed Hatch-Waxman dispute with limited precedential value and greater importance for understanding Ferring’s historical lifecycle strategy.

Its commercial lessons are:

• Ferring relied on formulation patents because mesalamine itself was not patent-protected as a new chemical entity.
• Apotex’s challenge demonstrated that the product’s principal barrier was vulnerable to ANDA litigation.
• The absence of a public merits judgment leaves no definitive holding that the asserted formulation claims were valid or infringed.
• Generic entry risk increased as the relevant patent terms expired.
• The case should be analyzed alongside other Ferring mesalamine cases rather than as an isolated test of the entire Pentasa patent estate.

Key Takeaways

• Ferring B.V. v. Apotex, Inc., No. 2:12-cv-01941, was a District of New Jersey Hatch-Waxman case involving generic mesalamine.
• The dispute concerned Ferring’s controlled-release formulation technology and included U.S. Patent No. 6,773,720.
• Apotex’s ANDA triggered a Paragraph IV patent challenge and statutory litigation stay.
• The case ended without a reported trial judgment finally resolving patent validity or infringement.
• The public record does not establish a precise settlement-based generic launch date.
• Ferring’s patent protection was formulation-based, not composition-of-matter protection.
• Biosimilar law was not relevant.
• Generic entry risk became the central commercial issue as the formulation patents expired or lost practical blocking power.

FAQs About Ferring B.V. v. Apotex

Was Ferring v. Apotex a patent-infringement case?

Yes. It was an ANDA-based patent-infringement action under the Hatch-Waxman Act.

What drug did Apotex seek to copy?

Apotex sought approval for a generic mesalamine extended-release product associated with Ferring’s Pentasa product franchise.

Did Ferring win the case?

There was no reported merits judgment confirming that Ferring prevailed on patent validity and infringement. The matter ended without a public trial decision.

Was U.S. Patent No. 6,773,720 listed in the Orange Book?

The ’720 patent was materially associated with Ferring’s controlled-release mesalamine products and was central to the relevant patent estate. Orange Book status must be evaluated against the specific NDA and product listing.

Can Apotex market a generic mesalamine product today?

The answer depends on the specific ANDA, FDA approval status, product strength, applicable patents, regulatory exclusivity, and any settlement restrictions. The 2012 lawsuit alone does not determine current marketing rights.

References

1. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

2. U.S. District Court for the District of New Jersey. (2012). Ferring B.V. v. Apotex, Inc., No. 2:12-cv-01941. PACER docket.

3. U.S. Patent and Trademark Office. (2004). U.S. Patent No. 6,773,720, controlled release compositions. Washington, DC: U.S. Department of Commerce.

4. U.S. Food and Drug Administration. (2024). Pentasa prescribing information. FDA.

5. U.S. Code, 35 U.S.C. § 271(e)(2). (2024). Infringement based on submission of an ANDA.